In pulmonary arterial hypertension, GLP-1 receptor agonists significantly lowered the risk of right heart failure compared ...

Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

Among nearly 10,000 GLP-1 receptor agonist prescriptions given at a single health system, 60.1% were filled, reported Ameet ...

Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is increasing in clinical trials to treat overlapping ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before surgery rose 16-fold among patients undergoing metabolic and bariatric surgery from 2020 to 2024.

People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems.

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial ...